<< China Sky One Medical reports financial results for third-quarter 2009 | YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文

Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study

Published on November 17, 2009 at 7:50 AM · No Comments

Anacor Pharmaceuticals today announced that it has dosed the first patient in a Phase I clinical study for AN3365, a novel boron-based, small-molecule drug candidate in development for the treatment of hospital infections caused by Gram-negative bacteria. The study will evaluate the safety, tolerability and pharmacokinetics of AN3365 in healthy volunteers.

AN3365 targets the bacterial enzyme leucyl tRNA synthetase. Preclinical studies suggest that AN3365 could be a novel approach for the treatment of Gram-negative infections, including E. coli, K. pneumoniae and Enterobacter spp. AN3365 is being developed under an alliance agreement with GlaxoSmithKline (GSK), and the initiation of Phase I studies releases a milestone payment to Anacor of $6 million.

“We are pleased with the rapid pace of our joint discovery activities, which have resulted in our second major milestone payment from GlaxoSmithKline in 2009,” said Jacob J. Plattner, Ph.D., Senior Vice President of Research at Anacor Pharmaceuticals. “By leveraging the novel approaches we’ve pioneered in the field of boron chemistry, and the expertise from GlaxoSmithKline, we were able to move this program from discovery to clinical development in just two years since signing the collaboration.”

The randomized, double-blind, placebo-controlled, dose-escalation study is expected to enroll more than 80 healthy volunteers. Participants in the Phase I study will receive AN3365 in single or multiple doses for treatment durations of up to 14 days.

Alliance with GSK

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading